Cover Image
市場調查報告書

神經損傷:開發平台分析

Nerve Injury - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200472
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
神經損傷:開發平台分析 Nerve Injury - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 70 Pages
簡介

神經損傷是神經組織的損傷,會造成肌肉無力或麻痺。此外皮膚還會部分失去感覺。症狀有站立暈眩、便秘、膀胱功能障礙、肌肉委縮、麻痺、燙傷般刺痛感、性功能障礙等。

本報告提供神經損傷的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

神經損傷 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Acorda Therapeutics, Inc.
  • Calico LLC
  • Convergence Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Kolon Life Science, Inc.
  • Medtronic, Inc.
  • Neuralstem, Inc.
  • Neurotune AG
  • Pfizer Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 3K3A-APC
  • cimaglermin alfa
  • CLP-257
  • CNV-1014802
  • KLS-Nst
  • MDT-15
  • NSI-566
  • NT-1654
  • Small Molecules to Activate NAMPT for Neurological Disorders
  • Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury
  • WAY-258131

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8269IDB

Summary

Global Markets Direct's, 'Nerve Injury - Pipeline Review, H2 2016', provides an overview of the Nerve Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nerve Injury
  • The report reviews pipeline therapeutics for Nerve Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nerve Injury therapeutics and enlists all their major and minor projects
  • The report assesses Nerve Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nerve Injury

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nerve Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nerve Injury Overview
  • Therapeutics Development
    • Pipeline Products for Nerve Injury - Overview
    • Pipeline Products for Nerve Injury - Comparative Analysis
  • Nerve Injury - Therapeutics under Development by Companies
  • Nerve Injury - Therapeutics under Investigation by Universities/Institutes
  • Nerve Injury - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Nerve Injury - Products under Development by Companies
  • Nerve Injury - Products under Investigation by Universities/Institutes
  • Nerve Injury - Companies Involved in Therapeutics Development
    • Biogen, Inc.
    • BrainStorm Cell Therapeutics Inc.
    • Calico LLC
    • F. Hoffmann-La Roche Ltd.
    • Human Stem Cells Institute
    • Medtronic plc
    • Neuralstem, Inc.
    • Neurotune AG
    • SanBio, Inc.
    • TissueGene, Inc.
  • Nerve Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLP-257 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDT-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neovasculgen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-1654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • raxatrigine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-618 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Peripheral Nerve Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit CaMKII for Stroke and Nerve Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-N - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nerve Injury - Dormant Projects
  • Nerve Injury - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nerve Injury, H2 2016
  • Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Nerve Injury - Pipeline by Biogen, Inc., H2 2016
  • Nerve Injury - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016
  • Nerve Injury - Pipeline by Calico LLC, H2 2016
  • Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Nerve Injury - Pipeline by Human Stem Cells Institute, H2 2016
  • Nerve Injury - Pipeline by Medtronic plc, H2 2016
  • Nerve Injury - Pipeline by Neuralstem, Inc., H2 2016
  • Nerve Injury - Pipeline by Neurotune AG, H2 2016
  • Nerve Injury - Pipeline by SanBio, Inc., H2 2016
  • Nerve Injury - Pipeline by TissueGene, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Nerve Injury - Dormant Projects, H2 2016
  • Nerve Injury - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Nerve Injury, H2 2016
  • Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top